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Although leukocytes infiltrate the kidney during ischemic
acute kidney injury (AKI) and release interleukin 6 (IL6), their
mechanism of activation is unknown. Here, we tested
whether Toll-like receptor 4 (TLR4) on leukocytes mediated
this activation by interacting with high-mobility group
protein B1 (HMGB1) released by renal cells as a consequence
of ischemic kidney injury. We constructed radiation-induced
bone marrow chimeras using C3H/HeJ and C57BL/10ScNJ
strains of TLR4 (/) mice and their respective TLR4 (þ /þ )
wild-type counterparts and studied them at 4h after an
ischemic insult. Leukocytes adopted from TLR4 (þ /þ ) mice
infiltrated the kidneys of TLR4 (/) mice, and TLR4 (/)
leukocytes infiltrated the kidneys of TLR4 (þ /þ ) mice but
caused little functional renal impairment in each case.
Maximal ischemic AKI required both radiosensitive
leukocytes and radioresistant renal parenchymal and
endothelial cells from TLR4 (þ /þ ) mice. Only TLR4 (þ /þ )
leukocytes produced IL6 in vivo and in response to HMGB1
in vitro. Thus, following infiltration of the injured kidney,
leukocytes produce IL6 when their TLR4 receptors interact
with HMGB1 released by injured renal cells. This underscores
the importance of TLR4 in the pathogenesis of ischemic AKI.
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Ischemic acute kidney injury (AKI) is ameliorated after
transgenic knockout of the Toll-like receptor 4 (TLR4) gene1
in C57BL/6 mice.2–5 However, the precise mechanisms of how
TLR4 regulates ischemic AKI remain to be fully elucidated.
Most attention has previously been directed at TLR4 on renal
tubules.2,5 The major goal of this manuscript is to determine
whether TLR4 on leukocytes, in addition to tubules, has a
major impact on ischemic AKI. This is an important question
because many leukocytes do express TLR4,6–9 renal leuko-
cytes do exacerbate ischemic AKI,10–15 and we do not fully
understand how renal leukocytes are activated during
ischemic AKI. An attractive hypothesis would be activation
via interactions between TLR4 on leukocytes and the TLR4
ligand high-mobility group protein B1 (HMGB1) released by
renal cells injured during ischemic AKI.16–20 Previous efforts
to determine the role of TLR4 on leukocytes have used bone
marrow (BM) chimeras between TLR4 (þ /þ ) and TLR4
(/) mice to examine the contribution of TLR4 on
radiosensitive BM-derived cells (presumably leukocytes)
and TLR4 on radioresistant renal parenchymal cells. These
studies have yielded conflicting results.2,3 We will use a
combination of techniques to address this issue. We will
reevaluate ischemic AKI in BM chimeras constructed
with high-dose irradiation, and we will also analyze
TLR4 expression in kidneys from chimeric mice. We will
develop techniques to isolate leukocytes from TLR4 (þ /þ )
versus TLR4 (/) kidneys, and then determine whether
TLR4 on leukocytes is required for their production of
interleukin 6 (IL6), which is known to exacerbate ischemic
AKI.21,22
The beneficial effect of TLR4 inactivation on ischemic AKI
was previously based on transgenically knocking out TLR4 in
a single mouse strain.2,3 Attempts to extend results from a
single strain of inbred mouse to outbred humans has
sometimes led to disappointment because modifier genes in
the outbred genetic background canceled the effect of the
knockout.23–25 We now demonstrate the effects in TLR4
mutation in several strains of mice; this suggests that these
effects are sufficiently powerful to overcome any modifier
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genes. Considering modifier genes is especially cogent for
ischemic AKI because the genetic background does affect the
course of this disease26 and other genes, in addition to TLR4,
affect ischemic AKI27–31 and could interact with TLR4.
Finally, we will use spontaneous mutations of TLR4. These
overcome the possibility of unintended effects on ischemic
AKI of the neomycin cassette, and 129 genetic materials
introduced into the C57BL/6 genome during the transgenic
knockout of TLR4 (refs 1, 25) used in previous studies.2,3
RESULTS
Spontaneous mutations of TLR4 on different genetic
backgrounds ameliorate ischemic AKI
We compare ischemic AKI in the TLR4 (/) C3H/ HeJ
mouse with its wild-type progenitor, and ischemic AKI in the
TLR (/) C57BL/10ScNJ with its wild-type progenitor. The
former C3H genetic background is unrelated both by
genealogy32 and also by single-nucleotide polymorphism
analysis33 from the previously studied C57BL/6 mouse.2,3 The
latter C57BL/10 genetic background is also significantly
different from the previously studied mouse.34,35 The TLR4
(/) C3H/HeJ has a spontaneous point mutation in the
cytoplasmic part of TLR4 that prevents known intracellular
signaling.36–42 The C57BL/10ScNJ has a complete deletion
mutation of TLR4.41–44
Both mutations provided protection from ischemic AKI.
Figure 1a and b show that both mutant mice have less
functional impairment than their wild-type counterparts.
Examination of renal histology showed that both mutant
mice also had less injury and less inflammation at 24 h
reperfusion. This pathology is summarized as morphometry
in Figure 2, and representative photomicrographs are shown
in Supplementary Figure S1AB online, Supplementary
Figure S1CD online, and Figure 3. Morphometry was
performed by our renal pathologist, Dr Zhou. He neither
knew the mouse strain nor treatment when he scored the
renal pathology. Note that Figure 3c shows that although
there was much less injury in the TLR4 (/) kidneys, some
necrosis in the outer medulla was present. In addition to the
point and null mutations discussed above, we also treated
ischemia AKI in wild-type mice with anti-TLR4 antibodies.
This also ameliorated ischemic AKI (Figure 4).
BM chimeras show that TLR4 on both radioresistant and
radiosensitive cells are required for maximal injury after
acute ischemia
Using the spontaneous inactivating TLR4 mutations above,
our major goal is to determine whether TLR4 on leukocytes
participates in ischemic AKI. We used a number of
techniques to address this question. We first used BM
chimeras between TLR4 (/) and TLR4 (þ /þ ) mice to
determine whether the TLR4 cells contributing to ischemic
AKI are radioresistant or radiosensitive (presumably
leukocytes). We made BM chimeras between C3H/HeJ
(TLR4 /) and C3H/HeOuJ TLR4 (þ /þ ) mice, and
found that maximal ischemic AKI requires functional TLR4
on both radiosensitive leukocytes and radioresistant renal
parenchymal cells. See Figure 5. As these mice differ only in a
point mutation, it was not possible to confirm success of the
BM transplant by genomic PCR of the blood.
Such independent confirmation was possible when we
studied chimeras of C57BL/10ScNJ (TLR4 (/)) and
C57BL/10SnJ (TLR4 (þ /þ )) mice (Figure 6). Figure 6a
shows our PCR strategy for detecting the TLR4 deletion
versus wild-type TLR4. Figure 6b shows confirmation of the
various chimeras by genomic PCR for TLR4 in their blood
leukocytes versus their radioresistant tails. We confirmed the
chimerism of all mice before inducing ischemic AKI.
Figure 6c shows that maximal ischemic AKI required
major contributions from both radioresistant and radio-
sensitive cells.
Overall, these two sets of chimeras, involving two different
pairs of TLR4 (þ /þ )/TLR4 (/) mice, suggest that
radiosensitive leukocytes are required for the pathogenesis of
ischemic AKI. We now use additional techniques to test this
requirement.
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Figure 1 | Spontaneous mutations in Toll-like receptor 4
(TLR4) ameliorate ischemic acute kidney injury as assessed by
renal function. In both a and b, n¼ 5, means and standard errors
are shown. Po0.05 between the TLR4 (þ /þ ) versus the
TLR4 (/) at 1- and 3-day reperfusion.
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TLR4 (þ /þ ) leukocytes are found in the inner stripe of the
outer medulla of TLR4 (/)-irradiated recipient kidneys
after ischemic AKI
If TLR4 (þ /þ ) leukocytes are required for ischemic AKI, we
predict that they, like other leukocytes,13,45–47 should
infiltrate the inner stripe of the outer medulla (ISOM) after
ischemic injury (Figure 7). In other words, we should find
TLR4 (þ /þ ) leukocytes in the ISOM of chimeras where
TLR4 (/)-irradiated hosts receive TLR4 (þ /þ ) BM
(group C of Figure 7a). TLR4-positive leukocytes are difficult
to demonstrate by immunohistology, perhaps because they
express very little TLR4.48 We therefore used an alternative
approach to test our prediction; we dissected the various
regions of the kidney and analyzed the regions for TLR4 by
quantitative reverse transcriptase-PCR. The results below
suggest that TLR4 (þ /þ ) leukocytes do indeed infiltrate the
ischemic ISOM.
At 4 h reperfusion, gross changes in the ischemic kidney
allow its dissection into three separate compartments:49–51
The first compartment is the ISOM and is distinguished by
congestion of red cells (Supplementary Figure S2 online).
The second compartment consists of the cortexþOSOM
(outer stripe of the outer medulla) and is identified as the
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Figure 2 | Spontaneous mutations in Toll-like receptor 4
(TLR4) ameliorate ischemic acute kidney injury—
morphometrics of injury and inflammation. Morphometry
calculated according to Thurman et al.86 injury was scored on a
scale of 0–5, where 0 was no tubular injury and 5 was maximal
tubular injury. The number of inflammatory cells was also
counted. Kidneys were harvested at 24 h reperfusion. Mean and
standard errors are shown. hpf, high-power field.
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Figure 3 | Spontaneous Toll-like receptor 4 (TLR4)-inactivating
mutation in C3H/HeJ mice ameliorates the pathology of
ischemic acute kidney injury. (a) Representative pathology of
TLR4 (þ /þ ) kidneys at 24 h reperfusion. C, cast in tubule;
G, glomerulus; N, severely damaged necrotic tubule that has
disintegrated. (b) Representative pathology of TLR4 (/) kidneys
at 24 h reperfusion. (c) Enlargement of the boxed area of b.
Three necrotic tubules (*) in the outer medulla of the TLR4 (/)
kidneys.
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Figure 4 |Anti-Toll-like receptor 4 (TLR4) antibody
ameliorates ischemic acute kidney injury in wild-type (C57BL/
10ScNJ) mice. n¼ 4 for each group. Mean and standard errors are
shown. *Po0.05 between groups. Mice received anti-TLR4 or
isotype control antibody intravenously 3 h before ischemia, and
serum creatinine was measured at 24 h reperfusion.
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pale structure outside the congested ISOM. The third
compartment is the inner medulla and is identified by its
characteristic papillary shape. In contrast to the ischemic
kidney, there is no vascular congestion in the ISOM of the
sham kidney, and this region cannot be distinguished from
the OSOMþ cortex. Thus, to compare sham with ischemic
kidneys, we dissected the kidneys into two compartments.
One contained the ISOMþOSOMþ cortex and the other
contained the inner medulla (papilla).
Analysis of TLR4 by quantitative reverse transcriptase-
PCR in these compartments demonstrated that ischemia
increased renal TLR4 in the chimeras of TLR4 (þ /þ ) BM to
irradiated TLR4 (/) recipients (Figure 7a, group C). This
increased TLR4 was in the ISOM (Figure 7b). This
observation is consistent with the prediction that TLR4
(þ /þ ) leukocytes infiltrate the ISOM after ischemia.
However, there was little ischemic AKI in this chimera
(Figure 6, group C), because TLR4 was also required on the
radioresistant cells. This issue is addressed in the Discussion
section.
Ischemia also increased renal TLR4 in the TLR4 (/)
BM to TLR4 (þ /þ )-irradiated recipient (Figure 7a,
group B). The ISOM had greater increases in TLR4 than
the cortex and OSOM (Figure 7c). Increased TLR4 on
radioresistant cells in the ISOM is consistent with ischemia,
directly increasing TLR4 expression on endothelia of the
ISOM.52 The results are consistent with the importance of
leukocyte TLR4 in the pathogenesis of ischemic AKI because
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Figure 6 |Maximal ischemic acute kidney injury requires Toll-like receptor 4 (TLR4) in both radiosensitive and -resistant cells:
chimeras between C57BL/10ScNJ and C57BL/10SnJ mice. (a) The specific PCR primers for a region within the TLR4 gene (fine arrows)
result in a 390-bp amplicon only in TLR4 (þ /þ ) cells. The primers flanking the wild-type TLR4 gene do not yield a product in TLR4 (þ /þ )
cells because of the large size of the TLR4 gene, but do result in a 140-bp amplicon in TLR4 (/) cells. (b) The insets show representative
genomic PCR of the tail and peripheral blood (P.blood) of the bone marrow (BM) chimeras. (c) The serum creatinine at the indicated days of
reperfusion in the various chimeric mice. No ischemia, serum creatinine taken before ischemia. The symbols are defined in b. *Po0.05
between the TLR4 (þ /þ ) BM to TLR4 (þ /þ ) chimera versus each other group at days 1 and 3 of reperfusion.
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despite the increased TLR4 on radioresistant cells, there was
little functional renal impairment in these chimeras (group B,
Figure 6). This may be due to the absence of leukocyte TLR4
in these chimeras.
We also found increased TLR4 in the ISOM during
ischemic AKI when both radiosensitive and -resistant cells
expressed TLR4 (Figure 7a, group A—TLR4 (þ /þ ) BM to
TLR4 (þ /þ ), and Figure 7d). This is consistent with the
direct ischemia-induced increased endothelial TLR4 that we
previously reported,52 plus infiltration with TLR4 (þ /þ )
leukocytes. Expression of TLR4 on both radiosensitive
and -resistant cells was associated with functional impairment
(group A, Figure 6). This confirmed that the radiation
chimeras responded similarly to the intact TLR4 (þ /þ )
mouse after clamping the renal pedicle for 17 min.
Only TLR4 (þ /þ ) CD45þ renal leukocytes produce mal-
adaptive IL6 in response to HMGB1 during ischemic AKI
If TLR4 (þ /þ ) leukocytes are required for maximal
ischemic AKI, we predict that these leukocytes should
produce maladaptive cytokines in response to TLR4 ligands
released by renal cells injured during ischemic AKI. Before
testing this prediction, we show that renal leukocytes do
indeed express TLR4 protein. Although previous work
showed that ischemia/reperfusion increased TLR4-expressing
interstitial cells,2 and increased leukocytes in the outer
medulla,53 the TLR4-expressing cells were not formally
identified as leukocytes. We now show increased
macrophages at 4 h reperfusion by immunofluorescence
(Figure 8a–c). We were unable to double immunostain with
macrophage markers and TLR4. Therefore, we isolated these
macrophages from wild-type ischemic kidneys by density
centrifugation and adherence to slides, and showed that they
all expressed both the TLR4 protein and the macrophage
marker F4/80 by double immunofluorescence (Figure 8d–f).
We chose to study IL6 production by TLR4 (þ /þ ) versus
(/) renal leukocytes. This choice was based on four
facts: the known detrimental effect of IL6 in ischemic
AKI as previously demonstrated by the beneficial effect of
anti-IL6 antibodies and transgenic knockout of IL6,21,22 the
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Figure 7 | Toll-like receptor 4 (TLR4) expression in the chimeric kidney during ischemic acute kidney injury: bone marrow (BM)
chimera constructed between TLR4 (/) C57BL/10ScNJ and TLR4 (þ /þ ) C57BL/10J mice. Chimeras constructed as in Figure 7.
Kidneys harvested at 4 h reperfusion. (a) TLR4 in sham versus ischemic chimeric kidneys. The ischemic kidneys were then dissected into the
inner stripe of the outer medulla (ISOM) versus the combined cortexþ outer stripe of the outer medulla (OSOM), and TLR4 compared. (b)
TLR4 in ischemic TLR4 (þ /þ ) BM to TLR4 (/) kidneys. (c) TLR4 in ischemic TLR4 (/) BM to TLR4 (þ /þ ) kidneys. (d) TLR4 in ischemic
TLR4 (þ /þ ) BM to TLR4 (þ /þ ) kidneys. The x axis is the TLR4 mRNA determined by quantitative reverse transcriptase-PCR by the
comparative cycle threshold (Ct) method. The TLR4 Ct is normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Ct from the
same sample. The calibrator gene is the TLR4 in the sham kidney from the group C in panel a. N¼ 3; the mean and standard errors are
shown. *Po0.05 between groups.
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requirement for IL6 wild-type BM cells for maximal ischemic
injury in chimeras involving IL6 knockout and wild-type
mice, and the ability of molecules released by injured S3
proximal tubules to stimulate IL6 production by macro-
phages in vitro.22 Furthermore, stimulation of the TLR4
receptor is known to stimulate leukocyte IL6 production.54
Although most research has focused on TLR4 on macro-
phages and dendritic cells,6 TLR4 is also found on T cells,7
polymorphonuclear cells,8 and natural killer cells,9 and
production of IL6 by these renal leukocytes may result from
any of these leukocytes interacting with TLR4 ligands,
Therefore, in some of the experiments below, we choose to
isolate all of these leukocytes together using a common
leukocyte cell surface marker—CD45.
We used three different approaches to determine whether
leukocytes produce maladaptive IL6 in a TLR4-dependent
manner. (a) We used anti-CD45-conjugated Dynabeads
(Invitrogen, Carlsbad, CA) to retrieve leukocytes from
enzymatically dispersed kidneys. Figure 9 shows that
leukocytes from TLR4 (þ /þ ), but not TLR4 (/),
kidneys express IL6 in vivo after ischemia. (b) To further
determine whether production of maladaptive IL6 by these
a d
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Ischemic high power 
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Figure 8 | Toll-like receptor 4 (TLR4) macrophages infiltrate the inner stripe of the outer medulla at 4 h reperfusion. (a) Low-power
view of non-ischemic kidney stained with F4/80 and 40,6-diamidino-2-phenylindole (DAPI). (b) Low-power view of ischemic kidney similarly
stained. (c) High-power view of ischemic kidney similarly stained. (d–f) Renal leukocytes isolated by enzymatic dispersion, gradient
centrifugation, and adherence at 4 h reperfusion. (d) Stained with F4/80 for macrophages (green fluorescence). (e) Merged d and f; F4/80
(green), TLR4 (red), and DAPI (blue). (f) Stained with TLR4 (red). White arrow in all three panels shows one of many leukocytes that stain both
for F4/80 and TLR4, and also for nuclear DAPI. T, tubule.
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Figure 9 | Interleukin 6 (IL6) expressed only by CD45þ leukocytes
from Toll-like receptor 4 (TLR4; þ /þ ) ischemic kidneys.
AKI, acute kidney injury; GAPDH, glyceraldehyde
3-phosphate dehydrogenase.
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leukocytes was due to stimulation of their TLR4 receptors, we
stimulated BM-derived macrophages with the TLR4 ligand
HMGB1 and heat shock protein 70 (HSP70) in vitro.
HMGB1 and HSP70 are ‘damage-associated molecular
pattern molecules’ (alarmin)16,17,18,19,20 and are released by
renal cells injured during ischemic AKI.2 Figure 10 shows that
HMGB1 stimulates IL6 production leukocytes from TLR4
(þ /þ ) mice to a much greater extent than HSP70; neither
stimulated leukocytes from TLR4 (/) mice. (c) Further-
more, we developed an in vitro model of ischemic AKI.22
Reactive oxygen species (ROS) are generated not only during
the reperfusion phase of ischemic AKI but also during
hypoxia because of inefficient use of residual oxygen by
mitochondria. Addition of ROS to renal tubular cells is an
established model of ischemia/reperfusion in vitro.55–60 In
this model (Figure 11), proximal tubule cells are injured by
ROS. The ROS-treated S3 proximal tubular cells release
HMGB1 into the tissue culture supernatant (Figure 11a and c).
The HMGB1-containing supernatant stimulates only TLR
(þ /þ ) macrophages to produce IL6 (Figure 11a and b). We
have previously demonstrated that ROS in the S3 supernatant
does not stimulate production of IL6 by macrophages.22
Although the concentration of HMGB1 in the supernatant
of injured S3 cells (Figure 11) is lower than the concentration
of purified HMGB1 necessary to stimulate macrophages
(Figure 10), HMGB1 in the supernatant is necessary for
stimulation of macrophages because inactivation of HMGB1
by glycyrrhizic acid markedly diminished the stimulatory
activity of the supernatant (Figure 12). Glycyrrhizic acid
specifically inactivates HMGB1 by specifically binding to
both active domains of HMGB1.61,62 Although the physio-
logical concentrations of HMGB1 in injured tissues is not
known, the concentration of purified HMGB1 that we used
in Figures 10 and 12 is similar to those used by others
in vitro.63 Why such large amounts of purified HMGB1 are
necessary to achieve the stimulation of lesser amounts of
HMGB1 in biological fluids is not known with certainty.
Explanations include the release of co-stimulatory cytokines
or post-translational modification of HMGB1 by stressed
cells so that HMGB1 in the supernatant is more stimulatory
than purified HMGB1.64,65
Endotoxin was not responsible for the stimulatory effect
of our HMGB1 (1690-HM, lot MHZ24 from R&D Systems,
Minneapolis, MN) that contained less than 0.00855 EU/mg.
Our HSP70 (ESP-f555, lot 0829062) containedo0.005 EU/mg.
Heat inactivated the stimulatory activity of our HMGB1 and
HSP70 by 98%; this indicates that it is a protein because
endotoxin is not inactivated by such heating.
DISCUSSION
In this manuscript, we further established the role of TLR4 in
ischemic AKI by using mice with spontaneous mutations that
inactivate TLR4. The C3H/HeJ and C57BL/10ScNJ strains
used in our report are unrelated both by their genealogy32
and also by single-nucleotide polymorphism analysis.33 The
fact that mutations in a single gene, TLR4, should have such
profound effects in such unrelated mice is an additional
powerful genetic argument for the great importance of TLR4
in the pathogenesis of ischemic AKI. This work confirms and
extends previous work that used a single transgenic knockout
of TLR4 on the C57BL/6 genetic background.2,3
In this manuscript, we suggest that TLR4-mediated
activation of leukocytes is one factor contributing to ischemic
AKI extension. We provide several lines of data consistent
with this hypothesis.
First, our radiation chimeras between two different pairs
of TLR4 (þ /þ ) and TLR4 (/) mice (C3H/HeJ and C3H/
HeOuJ, and C57BL/10ScNJ and C57BL/10SnJ) are strong
arguments for the participation of TLR4 on both radio-
resistant and radiosensitive (presumable leukocyte) cell
populations in the pathogenesis of ischemic AKI (Figures 5
and 6). Our data is consistent with Pulskens et al.3 but shows
a much greater contribution of radiosensitive TLR4 (þ /þ )
leukocytes compared with the report of Wu et al.2 The key
chimera is the TLR4 (/) BM in the TLR4 (þ /þ )-
irradiated recipient. The key question is whether all TLR4
(þ /þ ) BMs are eliminated by the irradiation. We and
Pulskens used two doses of 5 Gy for a total dose of 10 Gy,
whereas Wu 2 used one dose of 9 Gy. Our higher dose of
irradiation might have functionally eliminated all the TLR4
(þ /þ ) leukocytes in the irradiated TLR4 (þ /þ ) recipient.
In contrast, the smaller dose of irradiation in the Wu study
might have allowed a functionally significant number of
TLR4 (þ /þ ) leukocytes to survive in the irradiated
recipient. These survivors may have proliferated while the
mice were recovering from the irradiation and BM trans-
plant, and these survivors and their progeny may have
contributed to a TLR4 (þ /þ ) inflammatory response to
Control
TLR4 (+/+)
TLR4 (–/–)
HSP70
HMGB1
Control
HSP70
HMGB1
0 2 4 6 8 10 12 13 14
IL6/GAPDH mRNA
*
*
Figure 10 |High-mobility group protein B1 (HMGB1) and heat
shock protein 70 (HSP70) stimulate Toll-like receptor 4 (TLR4;
þ /þ ) but not TLR4 (/) bone marrow (BM)-derived
macrophages: BM-derived macrophages stimulated in vitro
with media, HSP70 (3 lg/ml), and HMGB1 (3 lg/ml). Interleukin
6 (IL6) was measured by quantitative reverse transcriptase-PCR.
Each sample normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). The calibrator gene is the media-treated
BMDM. n¼ 4. Means and standard deviation are shown. *Po0.05
between TLR4 (þ /þ ) media, HSP70, and HMGB1 groups. TLR4
(/) mice were C57BL/10ScNJ, and TLR4 (þ /þ ) mice were
C57BL/10SnJ.
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ischemia and the severe AKI seen in the Wu TLR4 (/) BM
to irradiated TLR4 (þ /þ ) recipient group.2
Second, we analyzed sham and ischemic kidneys from
chimeric mice. We found that TLR4 (þ /þ ) BM cells,
presumably leukocytes, infiltrate the ischemic kidney of TLR4
(/) recipients (group C, Figure 7a). This is consistent with
TLR4 expression by leukocytes and infiltration of these
TLR4-expressing leukocytes into the kidney in response to
ischemia. To our knowledge, this is the first such analysis of
TLR4 expression in ischemic kidneys from chimeric mice.
Despite the presence of TLR4 (þ /þ ) BM cells, presumed
leukocytes, in the ischemic kidneys of irradiated TLR4 (/)
recipients, there was little ischemic AKI in these chimeras
(Figure 6). One would expect that any TLR4 (þ /þ ) renal
leukocyte would be stimulated by HMGB1 released by
injured ischemic renal cells and would produce maladaptive
IL6, as discussed in the next paragraphs, and injure the
kidney. We believe that injury did not occur because although
a sufficient number of TLR4 (þ /þ ) leukocytes infiltrated
the TLR4 (/) kidneys to be detected, there was an
insufficient number to damage the kidney. We previously
showed that endothelial TLR4 is required for the increased
expression of adhesion molecules necessary for an efficient
inflammatory response to renal ischemia.52 Radioresistant
endothelial cells would be TLR4 (/) in the irradiated
TLR4 (/) recipient. Absent this endothelial TLR4, there
would be no increased adhesion molecule expression, and too
few TLR4 (þ /þ ) leukocytes would be able to infiltrate the
ischemic kidney significantly damage it.66 However, in wild-
type kidneys, endothelial TLR4 would be present, endothelial
adhesion molecules would therefore increase during ischemic
AKI, and there would be efficient inflammation by TLR4
(þ /þ ) leukocytes. Thus, both the TLR4 on radioresistant
endothelia and the TLR4 on radiosensitive leukocytes
Test supernatant 
for HMGB1 (see c)
HMGB1 (ng/ml)
Measure IL6 mRNA
from macrophages
(see b)
No treatment
ROS
Supernatant
+/– S3 cells
Stage |:
Generate
supernatant (SUP)
Stage |:
Resting S3 TLR4 (+/+)
macrophage
Resting S3 TLR4 (–/–)
macrophage
TLR4 (+/+) macrophages
TLR4 (–/–) macrophage
0.0 0.1
IL6 mRNA/housekeeping mRNA
0.2 0.3 0.4 0.5
*
S3 + ROS TLR4 (+/+)
macrophage
S3 + ROS TLR4 (–/–)
macrophage
Stage ||:
Stage ||:
Test supernatant for
macrophage 
activation
16.2 ± 2.4
0.0 ± 0.2
+/– ROS
Macrophages
Figure 11 |Reactive oxygen species (ROS)-injured S3 renal tubular cells release Toll-like receptor 4 (TLR4) ligands. (a) Experimental
design. In stage I, the SV40-transformed S3 tubules were a gift from Dr Glenn Nagami.83 If they were injured by ROS, they released
endogenous TLR4 ligands into their supernatant for 12 h. In stage II, the supernatant was cultured with murine bone marrow macrophages.
(b) Only TLR4 (þ /þ ) macrophages are activated by supernatant from ROS-stimulated S3 cells. TLR4 (þ /þ ) macrophages are from C57BL/
10SnJ mice. TLR4 (/) macrophages are from C57BL/10ScNJ mice. Results of typical experiment from four are shown. n¼ 3, mean and
standard error are shown. *Po0.05 between S3þ ROS/TLR4 (þ /þ ) macrophage and other groups by t-test. (c) High-mobility group
protein B1 (HMGB1) in supernatants. n¼ 4. Mean and standard errors shown. Po0.05 between no treatment and ROS groups. IL6,
interleukin 6.
Kidney International (2011) 80, 504–515 511
J Chen et al.: Leukocyte TLR4, IL6, and ischemic AKI o r ig ina l a r t i c l e
together cause the vigorous inflammatory response that
exacerbates ischemic AKI.
Consistent with the above reasoning, we did not find
statistically significant differences between IL6 mRNA when
TLR4 (/) BM was transplanted into TLR4 (þ /þ )
recipients versus when TLR4 (þ /þ ) BM was transplanted
into TLR4 / recipients. We believe that the similar low
levels of IL6 occurred in these two groups because the TLR4
(þ /þ ) leukocytes could not immigrate into the ischemic
TLR4 (/) renal tissue, as discussed above.
Third, we developed a technique for isolating renal
leukocytes from ischemic kidneys. We found that only
leukocytes from TLR4 (þ /þ ) kidneys produce maladaptive
IL621,22 during ischemic AKI in vivo (Figure 9).
Fourth, we also found that TLR4 (þ /þ ), but not TLR4,
(/) leukocytes produce IL6 in response to HMGB1
released by cells damaged during ischemia in vitro
(Figure 10).
Fifth, we demonstrate a role for TLR4 (þ /þ ) macro-
phages in an in vitro model of ischemic AKI. In this model,
proximal tubule cells release HMGB1 after injury by ROS and
this HMGB1 stimulates TLR4 (þ /þ ), but not TLR4 (/),
macrophages to produce IL6 (Figure 11). This increase in IL6
from macrophages can be attenuated by glycyrrhizic acid, an
inhibitor of HMGB161,62 (Figure 12).
The contribution of TLR4 (þ /þ ) leukocytes to the
pathogenesis of ischemic AKI, suggested by our data, is
consistent with the literature because of the known expres-
sion of TLR4 on leukocytes6–9 and the known contribution of
leukocytes to ischemic AKI.10–15 How leukocytes are activated
during ischemic AKI remains to be fully understood.
However, our data suggest that one pathway of activation is
stimulation of leukocyte TLR4 by HMGB1, which are
released by injured cells.
We acknowledge that other members of the family of
damage-associated molecular pattern molecules and their
ligands (for example, RAGE, TLR2, TLR9 and IL1) may also
participate in ischemic AKI.16,67–74 We chose to focus on the
HMGB1–TLR4 axis because direct molecular interactions
between HMGB1 and TLR4 have recently been demon-
strated,75 because antibodies against HMGB1 ameliorate
ischemic AKI,76,77 and transgenic knockout2–5 and sponta-
neous mutagenesis (Figures 1 and 2) and antibodies to TLR4
(Figure 4) ameliorate ischemic AKI. Furthermore, Figure 10
shows that another TLR4 ligand HSP70 also activates IL6
production by macrophages, but much less effectively than
HMGB1.
In conclusion, TLR4 was initially demonstrated on renal
tubular cells after 24 h reperfusion.2,3,78,79 We have recently
demonstrated endothelial expression of TLR4 at 4 h reper-
fusion and showed that renal endothelial TLR4 was required
for expression of adhesion molecules. These adhesion
molecules allow the maladaptive inflammatory response to
ischemic injury at 4-h reperfusion.52 In this manuscript, we
report that after leukocytes infiltrate the injured kidney, they
produce maladaptive IL6 when their TLR4 receptors interact
with HMGB1 released by injured renal cells. Thus, at least
three cell types (epithelia, endothelia, and leukocytes) express
TLR4 at various times during ischemic AKI; each may have
different roles during ischemic AKI.
MATERIALS AND METHODS
Renal ischemia/reperfusion injury
Six- to eight-week male TLR4 (/) C57BL/10ScNJ mice were
used. (This strain has other names—C57BL/10ScN, C57BL/
10ScNCr, and C57BL/10ScCr.) It has a deletion of TLR4 but a
normal IL12R. See http://jaxmice.jax.org/strain/003752.html), and
C3H/HeJ and the wild-type progenitor strains C57BL/10SnJ and
C3H/HeOuJ were purchased from the Jackson Laboratory (Bar
Harbor, Maine) or the National Cancer Institute (Frederick, MD). A
right nephrectomy and left renal pedicle occlusion were performed
under isoflurane anesthesia, while the rectal temperature was
maintained at 37 1C. Sham mice underwent the same procedure
except, instead of occluding the renal pedicle, the clip was placed
underneath the pedicle. The protocol was approved by the
Institutional Animal Care and Use Committee of UT Southwestern
Medical Center. Some mice received 30 mg of functional grade (no
NaN3), rat anti-mouse TLR4/MD2 monoclonal antibody (MTS510,
eBioscience, San Diego, CA) intravenously 3 h before renal ischemia.
Functional grade purified rat IgG2a isotype (eBioscience) was the
control.
BM chimeras
These were constructed as previously reported by our group.22,80
Briefly, recipient mice were irradiated with two doses of 5 Gy and
injected intravenously with 8 106 BM cells. After hematopoietic
reconstitution, mice were maintained in a sterile environment for
8–10 weeks before analyses for chimerism. Chimerism between the
C57BL/10ScNJ and C57BL/10J was confirmed by PCR using
published primers.81 Genomic DNA from tail and blood was
extracted using Extract-N-Amp Tissue/Blood PCR kit (Sigma,
St Louis, MO).
**
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Figure 12 | Inhibition of high-mobility group protein B1 by
glycyrrhizic acid prevents stimulation of Toll-like receptor 4
(TLR4; þ /þ ) macrophages. S3 cells treated with reactive
oxygen species (ROS) as in Figure 11. Their supernatant was
added to TLR4 (þ /þ ) macrophages in the presence or absence
of glycyrrhizic acid. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; IL6, interleukin 6.
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Leukocyte isolation from ischemic kidneys
Kidney tissues collected at 4-h reperfusion were minced into 1–2 mm
fragments and dissociated in phosphate-buffered saline with
Liberase Blendzyme 3 (Roche, Indianapolis, IN; 0.18 Wu¨nsch
U/ml) at 37 1C for 20 min. In all, 25 ml of Dynabeads Sheep
anti-rat IgG (Invitrogen) was coated with 1.5mg of rat anti-mouse
CD45 (30F11, eBioscience). Tissue digest was filtered through 70-
mm cell strainer (BD Falcon, Franklin Lakes, NJ). The single-cell
solution was then incubated with Dynabeads at 4 1C with gentle
tilting and rotation for 30 min. Total RNA was extracted from bead-
bound CD45þ cells using RNeasy Mini Kit (Qiagen, Valencia, CA).
BM-derived macrophages
Our technique for BM macrophage expansion came from Brunt
et al.82 By flow cytometry, over 95% of the expanded BM cells at
7 days were macrophages, as defined by their F4/80 positivity.
Macrophage cells were treated with either ROS-stressed S3 super-
natant, recombinant human HMGB1 (rhHMGB1, R&D Systems)
with or without 100 mmol/l glycyrrhizic acid (Sigma), or heat shock
protein 70 (Stressgen, San Diego, CA) for 4 h.
Treatment of S3 Cells with ROS
The SV-40 transformed S3 tubular cells83 were maintained as
previously described.84 Confluent cultures were serum starved
overnight and then placed into a solution containing 100 ml of
88 mg Hypoxanthine (Sigma)/ml in 1 mol/l Sodium Hydroxide
(Sigma) and 50 ml of Xanthine Oxidase (diluted 1:10 in DMEM/F12
(Invitrogen)). Supernatants were tested after 24 h of treatment.
Measurement of HMGB1 in ROS-stressed S3 supernatant:
HMGB1 protein was measured using HMGB1 ELISA Kit II according
to the manufacturer’s instructions (Shino Test, Tokyo, Japan).
Total RNA extraction and real-time reverse transcriptase-PCR
Kidney tissues were disrupted using PowerGen 700 homogenizer
(Fisher Scientific, Pittsburgh, PA). Total RNA was extracted by
RNeasy Midi Kit. Total RNA from the macrophage cells or CD45þ
cells was isolated using RNeasy Mini Kits, RNA was treated with
Turbo DNA-free kit (Applied Biosystems, ABI, Carlsbad, CA) to
remove genomic DNA. In all, 1 mg of total RNA was reverse
transcribed using High Capacity cDNA reverse transcription kit
(ABI). Confirmation and relative quantitation of TLR4 and IL6 were
performed using SYBR Green PCR Reagents and an ABI
StepOnePlus Real-time PCR System according to the manufacturer’s
instructions. Samples were analyzed in triplicate. Comparative cycle
threshold method was used. The cycle threshold of each gene of
interest was normalized to the glyceraldehyde 3-phosphate dehy-
drogenase cycle threshold determined under the same conditions.
The calibrator gene and the number of replicates are specified in
each figure legend.85 The results are expressed as the gene of interest/
glyceraldehyde 3-phosphate dehydrogenase mRNA. The specific
PCR primers (Integrated DNA Technologies, Coralville, IA) used
were as follows: TLR4, forward primer 50-AAACGGCAACTTGGA
CCTGA-30 and reverse primer 50-AGCTTAGCAGCCATGTGTTC
CA-30; IL6, forward primer 50-GGACCAAGACCATCCAATTCA-30
and reverse primer 50-CGCACTAGGTTTGCCGAGTAG-30.
Gradient cell isolation and immunohistochemistry
Mononuclear cells from ischemic kidneys at 4-h reperfusion were
isolated using 1-Step 1.077 Animal (Nycodenz, Accurate Chemical &
Scientific Corporation, Westbury, NY). Tissue dissociation was the
same as above. Tissue lysates were washed with phosphate-buffered
saline and loaded on top of Nycodenz, centrifuged at 600 g for
20 min with brake off. Cells harvested from the interface were
washed with phosphate-buffered saline at 400 g for 10 min. Cells
were resuspended with DMEM plus 10% FCS and cultured on 8-
well Nunc Lab-Tek II Chamber Slide System (Nalge Nunc
International, Rochester, NY) for overnight. Attached cells were
fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.1%
Triton X-100 for 3 min, and blocked with 10% goat serum for
30 min. For double staining of TLR4 and F4/80, monoclonal rat
anti-mouse TLR4 (R&D Systems), goat anti-rat-Texas Red (Vector
Laboratories, Burlingame, CA), rat anti-mouse F4/80-FITC
(eBioscience), and goat anti-FITC Alexa Fluor 488 (Invitrogen)
were sequentially applied to sections. VECTASHIELD Mounting
Medium with 40,6-diamidino-2-phenylindole (Vector Laboratories)
was used to stain the nuclei. Rat IgG2a was used as isotype control.
Fluorescent images were captured using Carl Zeiss Axioplan2
microscope (Carl Zeiss MicroImaging, Thornwood, NY). To prepare
ischemic kidney sections for F4/80 staining, the left kidney was in
situ perfused with cold phosphate-buffered saline and followed by
cold 4% paraformaldehyde. The kidney was removed, cut sagittally
and fixed in 4% paraformaldehyde at 4 1C for 2 h, and transferred
into 20% surcrose for cryoprotection. Kidney samples were then
embedded with OCT (Tissue-Tek, Sakura, Torrance, CA) and snap
frozen in isopentene on dry ice. Eight-micrometer thick sections
were cut on Leica Cryostat (Leica Microsystems, Richmond, IL)
and mounted onto superfrost-plus slides (Thermo Scientific,
Portsmouth, NH).
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